stockrow
Monday 9 November 2026
Export IKT’s income statement to Excel — free account
Inhibikase Therapeutics, Inc.
IKTInhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022.
- EPS
- 0.00%
- Free cash flow
- −123.2%
Quarter to June 2026, against a year earlier
1.50
0.06
+4.17%
Follow IKT
Alert me
Inhibikase Therapeutics, Inc. (IKT) P/E ratio
Inhibikase Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| PALI Palisade Bio, Inc. compare | 1.7× |
| PLX Protalix BioTherapeutics, Inc. compare | 10.6× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)